Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1 -Rearranged Non–Small Cell Lung Cancer

克里唑蒂尼 ROS1型 癌症研究 下调和上调 受体酪氨酸激酶 酪氨酸激酶 医学 肺癌 生物 C-Met公司 腺癌 癌症 信号转导 受体 病理 遗传学 基因 肝细胞生长因子 恶性胸腔积液
作者
Ahnah Song,Tae Min Kim,Dong‐Wan Kim,Soyeon Kim,Bhumsuk Keam,Se‐Hoon Lee,Dae Seog Heo
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:21 (10): 2379-2387 被引量:136
标识
DOI:10.1158/1078-0432.ccr-14-1350
摘要

PURPOSE: Although ROS1-rearranged non-small cell lung cancer (NSCLC) is sensitive to crizotinib, development of resistance is inevitable. Here, we identified molecular alterations in crizotinib-resistant tumors from two NSCLC patients with the CD74-ROS1 rearrangement, and in HCC78 cells harboring SLC34A2-ROS1 that showed resistance to crizotinib (HCC78CR cells). EXPERIMENTAL DESIGN: ROS1 kinase domain mutations were examined in fresh tumor tissues from two NSCLC patients and HCC78CR1-3 cells by direct sequencing. Ba/F3 cells expressing ROS1 secondary mutations were constructed to evaluate resistance to crizotinib. An upregulated pathway was identified using phospho-receptor tyrosine kinase array, EGFR signaling antibody array, and RNA sequencing (RNA-seq). Cell proliferation and ROS1 downstream signaling pathways were compared between HCC78 and HCC78CR1-3 cells. RESULTS: The ROS1 G2032R mutation was identified in crizotinib-resistant tumors from one patient. Furthermore, HCC78CR1 and CR2 cells harbored a novel ROS1 L2155S mutation (73.3% and 76.2%, respectively). ROS1 G2032R and L2155S mutations conferred resistance to crizotinib in Ba/F3 cells. Evidence of epithelial-to-mesenchymal transition with downregulated E-cadherin and upregulated vimentin was observed in HCC78CR1-2 cells and in the other patient. RNA-seq and EGFR signaling antibody array revealed that the EGFR pathway was significantly upregulated in HCC78CR3 versus HCC78 cells. Cells with the ROS1 mutation and upregulated EGFR were sensitive to foretinib, an inhibitor of c-MET, VEGFR2, and ROS1 and irreversible EGFR tyrosine kinase inhibitors plus crizotinib, respectively. CONCLUSIONS: Molecular changes associated with acquired crizotinib resistance in ROS1-rearranged NSCLC are heterogeneous, including ROS1 tyrosine kinase mutations, EGFR activation, and epithelial-to-mesenchymal transition.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美世界的应助被彩色炎彬采纳,获得10
刚刚
111舒舒发布了新的文献求助10
1秒前
Akim的应助被tlc_191026采纳,获得10
1秒前
科研菜鸡发布了新的文献求助10
3秒前
研友_VZG7GZ的应助被Elle采纳,获得30
3秒前
moonlighter完成签到,获得积分10
4秒前
4秒前
4秒前
水弘的应助被小熊饼干采纳,获得10
6秒前
7秒前
李健的应助被123y采纳,获得10
7秒前
闪闪灵完成签到 ,获得积分10
7秒前
9秒前
9秒前
李健的应助被脚踏实地i采纳,获得10
10秒前
111舒舒完成签到,获得积分10
11秒前
辛勤念之发布了新的文献求助10
11秒前
空白完成签到,获得积分10
11秒前
半糖糖发布了新的文献求助10
12秒前
CWJ发布了新的文献求助20
13秒前
Nefilibata发布了新的文献求助10
14秒前
Phil完成签到,获得积分10
15秒前
赘婿的应助被dzy采纳,获得10
15秒前
科研通AI65的应助被风吹麦浪采纳,获得10
16秒前
瘦瘦的语风完成签到,获得积分10
18秒前
18秒前
zxw发布了新的文献求助10
18秒前
nikange完成签到 ,获得积分10
19秒前
19秒前
JackieLiu的应助被zhazhao采纳,获得10
19秒前
JackieLiu的应助被zhazhao采纳,获得10
19秒前
19秒前
chen完成签到,获得积分10
20秒前
HH发布了新的文献求助30
21秒前
周芷卉完成签到 ,获得积分10
23秒前
香蕉寒珊发布了新的文献求助10
23秒前
crygni发布了新的文献求助10
23秒前
Pessica完成签到,获得积分20
24秒前
25秒前
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183449
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827509
捐赠科研通 7780646
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480371